

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT7069801

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
STEVE CARTT	10/08/2018
DAVID MEDEIROS	10/08/2018
GARRY THOMAS GWOZDZ	10/12/2018
ANDREW LOXLEY	10/25/2018
MARK MITCHNICK	10/15/2018
DAVID F. HALE	11/08/2018
EDWARD T. MAGGIO	10/08/2018
RECEIVING PARTY DATA	
Name:	HALE BIOPHARMA VENTURES, LLC
Street Address:	1042-B NORTH EL CAMINO REAL
Internal Address:	SUITE 430
City:	ENCINITAS
State/Country:	CALIFORNIA
Postal Code:	92024
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	17332800
CORRESPONDENCE DATA	
Fax Number:	(412)454-5060
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	(412)454-5000
Email:	docketingpgh@troutman.com
Correspondent Name:	TROUTMAN PEPPER HAMILTON SANDERS LLP
Address Line 1:	501 GRANT STREET, SUITE 300
Address Line 2:	UNION TRUST BUILDING
Address Line 4:	PITTSBURGH, PENNSYLVANIA 15219-4429
ATTORNEY DOCKET NUMBER:	148570.004361
NAME OF SUBMITTER:	KEVIN T. MALESIC
SIGNATURE:	/Kevin T. Malesic/

PATENT

DATE SIGNED:	12/13/2021
--------------	------------

Total Attachments: 9

source=4361_ParentAssignment_Executed_Inventors_to_HaleBiopharmaVentures#page1.tif
source=4361_ParentAssignment_Executed_Inventors_to_HaleBiopharmaVentures#page2.tif
source=4361_ParentAssignment_Executed_Inventors_to_HaleBiopharmaVentures#page3.tif
source=4361_ParentAssignment_Executed_Inventors_to_HaleBiopharmaVentures#page4.tif
source=4361_ParentAssignment_Executed_Inventors_to_HaleBiopharmaVentures#page5.tif
source=4361_ParentAssignment_Executed_Inventors_to_HaleBiopharmaVentures#page6.tif
source=4361_ParentAssignment_Executed_Inventors_to_HaleBiopharmaVentures#page7.tif
source=4361_ParentAssignment_Executed_Inventors_to_HaleBiopharmaVentures#page8.tif
source=4361_ParentAssignment_Executed_Inventors_to_HaleBiopharmaVentures#page9.tif

ASSIGNMENT OF APPLICATION

Docket Number 35401-716.303

WHEREAS, the undersigned:

- | | | |
|--|--|---|
| 1. CARTT, Steve
1055 Black Mountain Road
Hillsborough, CA 94010 | 2. MEDEIROS, David
1702 A Street, #C
Sparks, NV 89431 | 3. GWOZDZ, Garry Thomas
432 Pine Street
Jim Thorpe, PA 18229 |
| 4. LOXLEY, Andrew
Rue Emile Claus 42
Brussels, BE 1050 | 5. MITCHNICK, Mark
80 Three Mile Harbor Drive
East Hampton, NY 11937 | 6. HALE, David F.
12340 El Camino Real, Suite 425
San Diego, CA 92130 |
| 7. MAGGIO, Edward T.
11770 Bernardo Plaza Court
Suite 353
San Diego, CA 92128 | | |

(hereinafter "Inventor(s)), have invented certain new and useful improvements in the invention entitled

ADMINISTRATION OF BENZODIAZEPINE COMPOSITIONS

☒ for which Application No. 15/955,397 was filed on April 17, 2018 in the United States Patent Office.

WHEREAS, Hale Biopharma Ventures, LLC, a limited liability company of the state of California, having a place of business at 1042-B North El Camino Real, Suite 430, Encinitas, CA 92024, (hereinafter "Assignee"), is desirous of acquiring the entire right, title and interest in and to said Application(s) and the inventions disclosed therein, and in and to all embodiments of the inventions, heretofore conceived, made or discovered, whether jointly or severally, by said Inventor(s) (hereinafter collectively referred to as "Inventions"), and in and to any and all patents, inventor's certificates and other forms of protection (hereinafter "Patent(s)") thereon granted in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty.

NOW, THEREFORE, in consideration of good and valuable consideration acknowledged by said Inventor(s) to have been received in full from said Assignee:

1. Said Inventor(s) do hereby sell, assign, transfer and convey unto said Assignee the entire right, title and interest (a) in and to said Inventions, including the right to claim priority to said Inventions; (b) in and to all rights to all United States and corresponding non-United States patent applications and Patent(s), including those filed under the Paris Convention for the Protection of Industrial Property, The Patent Cooperation Treaty or otherwise; (c) in and to any and all applications filed and any and all Patent(s) granted on said Inventions in the United States, in any foreign country, or under any international convention, agreement, protocol, or treaty, including each and every application filed and any and all Patent(s) granted on any application which is a divisional, substitution, continuation, or continuation-in-part of any of said Application(s); and (d) in and to each and every reissue, reexamination, or extensions of any of said Patent(s).

2. Said Inventor(s) hereby covenant and agree to cooperate with said Assignee to enable said Assignee to enjoy to the fullest extent the right, title and interest herein conveyed in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty. Such cooperation by said Inventor(s) shall include prompt production of pertinent facts and documents, giving of testimony, execution of petitions, oaths, specifications, declarations or other papers, and other assistance all to the extent deemed necessary or desirable by said Assignee (a) for perfecting in said Assignee the right, title and interest herein conveyed; (b) for prosecuting any applications covering said Inventions; (c) for filing and prosecuting substitute, divisional, continuing or additional applications covering said Inventions; (d) for filing and prosecuting applications for reissuance of any said Patent(s); (e) for interference or other priority proceedings involving said Inventions; and (f) for legal proceedings involving said Inventions and any


applications therefor and any Patent(s) granted thereon, including without limitation reissues and reexaminations, opposition proceedings, cancellation proceedings, priority contests, public use proceedings, infringement actions and court actions; provided, however, that the expense incurred by said Inventor(s) in providing such cooperation shall be paid for by said Assignee.

3. The terms and covenants of this assignment shall inure to the benefit of said Assignee, its successors, assigns and other legal representatives, and shall be binding upon said Inventor(s), their respective heirs, legal representatives and assigns.

4. Said Inventor(s) hereby warrant and represent that they have not entered and will not enter into any assignment, contract, or understanding in conflict herewith.

5. Said Inventor(s) hereby request that any Patent(s) issuing in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, be issued in the name of the Assignee, or its successors and assigns, for the sole use of said Assignee, its successors, legal representatives and assigns.

IN WITNESS WHEREOF, said Inventor(s) have executed and delivered this instrument to said Assignee as of the dates written below:

Date: <u>10-8-18</u>		Date: _____	_____
	Steve Cart		Andrew Loxley
Date: _____	_____	Date: _____	_____
	David Medeiros		Mark Mitchnick
Date: _____	_____	Date: _____	_____
	Garry Thomas Gwozdz		David F. Hale
Date: _____	_____		
	Edward T. Maggio		

RECEIVED AND AGREED TO BY ASSIGNEE:

Hale Biopharma Ventures, LLC

Date: _____

By: _____
Name: David F. Hale
Title: Chief Executive Officer

applications therefor and any Patent(s) granted thereon, including without limitation reissues and reexaminations, opposition proceedings, cancellation proceedings, priority contests, public use proceedings, infringement actions and court actions; provided, however, that the expense incurred by said Inventor(s) in providing such cooperation shall be paid for by said Assignee.

3. The terms and covenants of this assignment shall inure to the benefit of said Assignee, its successors, assigns and other legal representatives, and shall be binding upon said Inventor(s), their respective heirs, legal representatives and assigns.

4. Said Inventor(s) hereby warrant and represent that they have not entered and will not enter into any assignment, contract, or understanding in conflict herewith.

5. Said Inventor(s) hereby request that any Patent(s) issuing in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, be issued in the name of the Assignee, or its successors and assigns, for the sole use of said Assignee, its successors, legal representatives and assigns.

IN WITNESS WHEREOF, said Inventor(s) have executed and delivered this instrument to said Assignee as of the dates written below:

Date: _____
Steve Cartt

Date: _____
Andrew Loxley

Date: 10/8/13 
David Medeiros

Date: _____
Mark Mitchnick

Date: _____
Garry Thomas Gwozdz

Date: _____
David F. Hale

Date: _____
Edward T. Maggio

RECEIVED AND AGREED TO BY ASSIGNEE:

Hale Biopharma Ventures, LLC

Date: _____

By: _____
Name: David F. Hale
Title: Chief Executive Officer

ASSIGNMENT OF APPLICATION	Docket Number 35401-716.303
----------------------------------	-----------------------------

WHEREAS, the undersigned:

1. CARTT, Steve 1055 Black Mountain Road Hillsborough, CA 94010	2. MEDEIROS, David 1702 A Street, #C Sparks, NV 89431	3. GWOZDZ, Garry Thomas 432 Pine Street Jim Thorpe, PA 18229
4. LOXLEY, Andrew Rue Emile Claus 42 Brussels, BE 1050	5. MITCHNICK, Mark 80 Three Mile Harbor Drive East Hampton, NY 11937	6. HALE, David F. 12340 El Camino Real, Suite 425 San Diego, CA 92130
7. MAGGIO, Edward T. 11770 Bernardo Plaza Court Suite 353 San Diego, CA 92128		

(hereinafter "Inventor(s)), have invented certain new and useful improvements in the invention entitled

ADMINISTRATION OF BENZODIAZEPINE COMPOSITIONS

☒ for which Application No. 15/955,397 was filed on April 17, 2018 in the United States Patent Office.

WHEREAS, Hale Biopharma Ventures, LLC, a limited liability company of the state of California, having a place of business at 1042-B North El Camino Real, Suite 430, Encinitas, CA 92024, (hereinafter "Assignee"), is desirous of acquiring the entire right, title and interest in and to said Application(s) and the inventions disclosed therein, and in and to all embodiments of the inventions, heretofore conceived, made or discovered, whether jointly or severally, by said Inventor(s) (hereinafter collectively referred to as "Inventions"), and in and to any and all patents, inventor's certificates and other forms of protection (hereinafter "Patent(s)") thereon granted in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty.

NOW, THEREFORE, in consideration of good and valuable consideration acknowledged by said Inventor(s) to have been received in full from said Assignee:

1. Said Inventor(s) do hereby sell, assign, transfer and convey unto said Assignee the entire right, title and interest (a) in and to said Inventions, including the right to claim priority to said Inventions; (b) in and to all rights to all United States and corresponding non-United States patent applications and Patent(s), including those filed under the Paris Convention for the Protection of Industrial Property, The Patent Cooperation Treaty or otherwise; (c) in and to any and all applications filed and any and all Patent(s) granted on said Inventions in the United States, in any foreign country, or under any international convention, agreement, protocol, or treaty, including each and every application filed and any and all Patent(s) granted on any application which is a divisional, substitution, continuation, or continuation-in-part of any of said Application(s); and (d) in and to each and every reissue, reexamination, or extensions of any of said Patent(s).

2. Said Inventor(s) hereby covenant and agree to cooperate with said Assignee to enable said Assignee to enjoy to the fullest extent the right, title and interest herein conveyed in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty. Such cooperation by said Inventor(s) shall include prompt production of pertinent facts and documents, giving of testimony, execution of petitions, oaths, specifications, declarations or other papers, and other assistance all to the extent deemed necessary or desirable by said Assignee (a) for perfecting in said Assignee the right, title and interest herein conveyed; (b) for prosecuting any applications covering said Inventions; (c) for filing and prosecuting substitute, divisional, continuing or additional applications covering said Inventions; (d) for filing and prosecuting applications for reissuance of any said Patent(s); (e) for interference or other priority proceedings involving said Inventions; and (f) for legal proceedings involving said Inventions and any

applications therefor and any Patent(s) granted thereon, including without limitation reissues and reexaminations, opposition proceedings, cancellation proceedings, priority contests, public use proceedings, infringement actions and court actions; provided, however, that the expense incurred by said Inventor(s) in providing such cooperation shall be paid for by said Assignee.

3. The terms and covenants of this assignment shall inure to the benefit of said Assignee, its successors, assigns and other legal representatives, and shall be binding upon said Inventor(s), their respective heirs, legal representatives and assigns.

4. Said Inventor(s) hereby warrant and represent that they have not entered and will not enter into any assignment, contract, or understanding in conflict herewith.

5. Said Inventor(s) hereby request that any Patent(s) issuing in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, be issued in the name of the Assignee, or its successors and assigns, for the sole use of said Assignee, its successors, legal representatives and assigns.

IN WITNESS WHEREOF, said Inventor(s) have executed and delivered this instrument to said Assignee as of the dates written below:

Date: _____ Steve Cartt	Date: 10/25/2018 DocuSigned by: <i>Andrew Loxley</i> DF8A1B0F64A54F8... Andrew Loxley
Date: _____ David Medeiros	Date: _____ Mark Mitchnick
Date: _____ Garry Thomas Gwozdz	Date: _____ David F. Hale
Date: _____ Edward T. Maggio	

RECEIVED AND AGREED TO BY ASSIGNEE:

Hale Biopharma Ventures, LLC

Date: _____

By: _____

Name: David F. Hale
Title: Chief Executive Officer

applications therefor and any Patent(s) granted thereon, including without limitation reissues and reexaminations, opposition proceedings, cancellation proceedings, priority contests, public use proceedings, infringement actions and court actions; provided, however, that the expense incurred by said Inventor(s) in providing such cooperation shall be paid for by said Assignee.

3. The terms and covenants of this assignment shall inure to the benefit of said Assignee, its successors, assigns and other legal representatives, and shall be binding upon said Inventor(s), their respective heirs, legal representatives and assigns.

4. Said Inventor(s) hereby warrant and represent that they have not entered and will not enter into any assignment, contract, or understanding in conflict herewith.

5. Said Inventor(s) hereby request that any Patent(s) issuing in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, be issued in the name of the Assignee, or its successors and assigns, for the sole use of said Assignee, its successors, legal representatives and assigns.

IN WITNESS WHEREOF, said Inventor(s) have executed and delivered this instrument to said Assignee as of the dates written below:

Date: _____
Steve Cartt

Date: _____
Andrew Loxley

Date: _____
David Medeiros

Date: 15-OCT-2018 Mark Mitchnick
Mark Mitchnick

Date: 12 Oct 2018 Garry Thomas Gwozdz
Garry Thomas Gwozdz

Date: _____
David F. Hale

Date: _____
Edward T. Maggio

RECEIVED AND AGREED TO BY ASSIGNEE:

Hale Biopharma Ventures, LLC

Date: _____

By: _____
Name: David F. Hale
Title: Chief Executive Officer

applications therefor and any Patent(s) granted thereon, including without limitation reissues and reexaminations, opposition proceedings, cancellation proceedings, priority contests, public use proceedings, infringement actions and court actions; provided, however, that the expense incurred by said Inventor(s) in providing such cooperation shall be paid for by said Assignee.

3. The terms and covenants of this assignment shall inure to the benefit of said Assignee, its successors, assigns and other legal representatives, and shall be binding upon said Inventor(s), their respective heirs, legal representatives and assigns.

4. Said Inventor(s) hereby warrant and represent that they have not entered and will not enter into any assignment, contract, or understanding in conflict herewith.

5. Said Inventor(s) hereby request that any Patent(s) issuing in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, be issued in the name of the Assignee, or its successors and assigns, for the sole use of said Assignee, its successors, legal representatives and assigns.

IN WITNESS WHEREOF, said Inventor(s) have executed and delivered this instrument to said Assignee as of the dates written below:

Date: _____
Steve Cartt


Date: _____
Andrew Loxley

Date: _____
David Medeiros

Date: _____
Mark Mitchnick

Date: _____
Garry Thomas Gwozdz

Date: _____
David F. Hale

Date: 8 Oct. 2018 
Edward T. Maggio

RECEIVED AND AGREED TO BY ASSIGNEE:

Hale Biopharma Ventures, LLC

Date: _____

By: _____

Name: David F. Hale

Title: Chief Executive Officer

ASSIGNMENT OF APPLICATION

Docket Number 35401-716.303

WHEREAS, the undersigned:

- | | | |
|--|--|---|
| 1. CARTT, Steve
1055 Black Mountain Road
Hillsborough, CA 94010 | 2. MEDEIROS, David
1702 A Street, #C
Sparks, NV 89431 | 3. GWOZDZ, Garry Thomas
432 Pine Street
Jim Thorpe, PA 18229 |
| 4. LOXLEY, Andrew
Rue Emile Claus 42
Brussels, BE 1050 | 5. MITCHNICK, Mark
80 Three Mile Harbor Drive
East Hampton, NY 11937 | 6. HALE, David F.
12340 El Camino Real, Suite 425
San Diego, CA 92130 |
| 7. MAGGIO, Edward T.
11770 Bernardo Plaza Court
Suite 353
San Diego, CA 92128 | | |

(hereinafter "Inventor(s)), have invented certain new and useful improvements in the invention entitled

ADMINISTRATION OF BENZODIAZEPINE COMPOSITIONS

☒ for which Application No. 15/955,397 was filed on April 17, 2018 in the United States Patent Office.

WHEREAS, Hale Biopharma Ventures, LLC, a limited liability company of the state of California, having a place of business at 1042-B North El Camino Real, Suite 430, Encinitas, CA 92024, (hereinafter "Assignee"), is desirous of acquiring the entire right, title and interest in and to said Application(s) and the inventions disclosed therein, and in and to all embodiments of the inventions, heretofore conceived, made or discovered, whether jointly or severally, by said Inventor(s) (hereinafter collectively referred to as "Inventions"), and in and to any and all patents, inventor's certificates and other forms of protection (hereinafter "Patent(s)") thereon granted in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty.

NOW, THEREFORE, in consideration of good and valuable consideration acknowledged by said Inventor(s) to have been received in full from said Assignee:

1. Said Inventor(s) do hereby sell, assign, transfer and convey unto said Assignee the entire right, title and interest (a) in and to said Inventions, including the right to claim priority to said Inventions; (b) in and to all rights to all United States and corresponding non-United States patent applications and Patent(s), including those filed under the Paris Convention for the Protection of Industrial Property, The Patent Cooperation Treaty or otherwise; (c) in and to any and all applications filed and any and all Patent(s) granted on said Inventions in the United States, in any foreign country, or under any international convention, agreement, protocol, or treaty, including each and every application filed and any and all Patent(s) granted on any application which is a divisional, substitution, continuation, or continuation-in-part of any of said Application(s); and (d) in and to each and every reissue, reexamination, or extensions of any of said Patent(s).

2. Said Inventor(s) hereby covenant and agree to cooperate with said Assignee to enable said Assignee to enjoy to the fullest extent the right, title and interest herein conveyed in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty. Such cooperation by said Inventor(s) shall include prompt production of pertinent facts and documents, giving of testimony, execution of petitions, oaths, specifications, declarations or other papers, and other assistance all to the extent deemed necessary or desirable by said Assignee (a) for perfecting in said Assignee the right, title and interest herein conveyed; (b) for prosecuting any applications covering said Inventions; (c) for filing and prosecuting substitute, divisional, continuing or additional applications covering said Inventions; (d) for filing and prosecuting applications for reissuance of any said Patent(s); (e) for interference or other priority proceedings involving said Inventions; and (f) for legal proceedings involving said Inventions and any

applications therefor and any Patent(s) granted thereon, including without limitation reissues and reexaminations, opposition proceedings, cancellation proceedings, priority contests, public use proceedings, infringement actions and court actions; provided, however, that the expense incurred by said Inventor(s) in providing such cooperation shall be paid for by said Assignee.

3. The terms and covenants of this assignment shall inure to the benefit of said Assignee, its successors, assigns and other legal representatives, and shall be binding upon said Inventor(s), their respective heirs, legal representatives and assigns.

4. Said Inventor(s) hereby warrant and represent that they have not entered and will not enter into any assignment, contract, or understanding in conflict herewith.

5. Said Inventor(s) hereby request that any Patent(s) issuing in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, be issued in the name of the Assignee, or its successors and assigns, for the sole use of said Assignee, its successors, legal representatives and assigns.

IN WITNESS WHEREOF, said Inventor(s) have executed and delivered this instrument to said Assignee as of the dates written below:


Date: _____
Steve Cartt

Date: _____
Andrew Loxley

Date: _____
David Medeiros

Date: _____
Mark Mitchnick

Date: _____
Garry Thomas Gwozdz


Date: November 8, 2018

David F. Hale

Date: _____
Edward T. Maggio

RECEIVED AND AGREED TO BY ASSIGNEE:

Hale Biopharma Ventures, LLC

Date: November 8, 2018

By: 
Name: David F. Hale
Title: Chief Executive Officer